Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Marina Talamonti, Giovanna Malara, Ylenia Natalini, Federico Bardazzi, Andrea Conti, Andrea Chiricozzi, Cristina Mugheddu, Paolo Gisondi, Stefano Piaserico, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Anna Balato, Francesco Loconsole, Annamaria Offidani, Claudio Bonifati, Francesca Prignano, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Medical Journals Sweden 2021-03-01
Rangatū:	Acta Dermato-Venereologica
Ngā marau:	anxiety depression psoriasis secukinumab quality of life
Urunga tuihono:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3712
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!